Pharmaceutical News

RSS

Study sheds light on fertility concerns of young breast cancer patients

Concerns about fertility kept a third of young women with breast cancer from taking tamoxifen, despite its known benefit in reducing the risk of breast cancer coming back.

25 Aug 2015

Study: Influenza vaccines offer sustained protection up to 6 months during flu season

Individuals who received the flu vaccine were protected for up to 6 months post-vaccination, the duration of most flu seasons, according to a study presented at the 2015 International Conference on Emerging Infectious Diseases.

25 Aug 2015

Researchers evaluate use of pharmacy-based naloxone education and distribution to fight opioid overdoses

In response to the growing opioid crisis, several states, including Massachusetts and Rhode Island, have granted pharmacists the authority to provide naloxone rescue kits without a prescription to at-risk patients. This model of pharmacy-based naloxone (PBN) education and distribution is one of the public health strategies currently being evaluated at hundreds of pharmacies in both states to determine the impact on opioid overdose death rates.

25 Aug 2015

Study shows beta blockers may benefit women with ovarian cancer

A new analysis of patient records indicates that certain drugs taken to improve heart health may also have anti-cancer properties.

25 Aug 2015

Accutest makes strategic expansion into Latin America to support the growth of pharmaceutical sector

Accutest Research Laboratories, a leading global Contract Research Organization (CRO), further pursues its strategic expansion into Latin America by opening offices and establishing operational presence in Brazil.

25 Aug 2015

TSRI, Janssen collaborate to find universal flu vaccine

Scientists from The Scripps Research Institute and the Janssen Pharmaceutical Companies of Johnson & Johnson have found a way to induce antibodies to fight a wide range of influenza subtypes—work that could one day eliminate the need for repeated seasonal flu shots.

24 Aug 2015

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Esperance Pharmaceuticals Inc. today announced that it has entered into a strategic alliance agreement with MD Anderson Cancer Center to accelerate the clinical development of its lead anti-cancer candidate EP-100 for the treatment of ovarian cancer and to collaborate on preclinical studies of EP-100 as a treatment for breast cancer.

24 Aug 2015

Beta-blockers improve overall survival among epithelial ovarian cancer patients

In a first-of-its-kind study, researchers demonstrate a benefit in overall survival among epithelial ovarian cancer (EOC) patients receiving generic heart medications known as beta-blockers. Survival was shown to be greatest among those prescribed first-generation nonselective beta-blockers.

24 Aug 2015

Researchers report new breakthrough in countering deadly effects of radiation exposure

An interdisciplinary research team led by The University of Texas Medical Branch at Galveston reports a new breakthrough in countering the deadly effects of radiation exposure. A single injection of a regenerative peptide was shown to significantly increase survival in mice when given 24 hours after nuclear radiation exposure.

24 Aug 2015

Alpha lipoic acid can stimulate telomerase with positive effects in mouse model of atherosclerosis

In human cells, shortened telomeres, the protective caps at the ends of chromosomes, are both a sign of aging and contribute to it. Scientists at Emory University School of Medicine have found that the dietary supplement alpha lipoic acid (ALA) can stimulate telomerase, the enzyme that lengthens telomeres, with positive effects in a mouse model of atherosclerosis.

24 Aug 2015

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics, an immuno-oncology company developing novel therapeutics for the treatment of cancer, today announced that the US Food and Drug Administration has granted Orphan Drug Designation for MTG-201, an advanced biologic therapy targeting Dickkopf-3 gene defects in various cancers, for the treatment of malignant mesothelioma.

23 Aug 2015

IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

Afatinib (trade name: Giotrif) has been approved since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).

21 Aug 2015

Novel synthetic DNA vaccine induces protective immunity against MERS virus in animal study

A novel synthetic DNA vaccine can, for the first time, induce protective immunity against the Middle East Respiratory Syndrome (MERS) coronavirus in animal species, reported researchers from the Perelman School of Medicine at the University of Pennsylvania.

21 Aug 2015

Medicaid could save billions as patents for several blockbuster antipsychotic medications expire

Medicaid is expected to save billions of dollars a year as patents for several blockbuster antipsychotic medications expire and use of generic versions of these drugs increases, according to a new study by researchers at the University of Maryland School of Medicine. These savings may provide relief from the high costs of these medications and allow policymakers to lift restrictions on patients' access, the researchers argue.

21 Aug 2015

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

Allergan plc, a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration has accepted the company's resubmission of its Supplemental Biologics License Application (sBLA) for BOTOX (onabotulinumtoxinA) for the treatment of adults with lower limb (involving ankle and toe muscles) spasticity in adults.

20 Aug 2015

PharmaMar to market and distribute APLIDIN drug candidate in Australia, New Zealand

PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company Specialised Therapeutics Australia Pty (STA) to market and distribute the drug candidate APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

New scientific conference 'Aspirin in the 21st Century' to be held in London

What more can be said about aspirin, a medicine that was first prescribed at the end of the 19th century? It is known and accepted in every country. For over a hundred years it has been the standard by which all other, newer, painkillers have had to be judged, and it has never been found to be inferior. It is still considered the world's leading analgesic.

20 Aug 2015

S1 Biopharma supports FDA's approval of flibanserin for women living with HSDD

S1 Biopharma is a developer of first-in-class drugs for sexual dysfunction in both women and men. The company's lead compound, Lorexys, is currently in Phase IIb for the treatment of hypoactive sexual desire disorder (HSDD).

20 Aug 2015

IQWiG finds no added benefit for safinamide in Parkinson disease

Safinamide (trade name: Xadago) has been available since February 2015 as add-on therapy for the treatment of mid- to late-stage Parkinson disease in adults. In combination with levodopa alone or together with other Parkinson disease medicinal products, this monoamine oxidase (MAO-B) inhibitor is used to help restore dopamine levels in the brain.

20 Aug 2015

Pharmaceutical News

Study sheds light on fertility concerns of young breast cancer patients

Study: Influenza vaccines offer sustained protection up to 6 months during flu season

Researchers evaluate use of pharmacy-based naloxone education and distribution to fight opioid overdoses

Study shows beta blockers may benefit women with ovarian cancer

Accutest makes strategic expansion into Latin America to support the growth of pharmaceutical sector

TSRI, Janssen collaborate to find universal flu vaccine

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Beta-blockers improve overall survival among epithelial ovarian cancer patients

Researchers report new breakthrough in countering deadly effects of radiation exposure

Alpha lipoic acid can stimulate telomerase with positive effects in mouse model of atherosclerosis

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

Novel synthetic DNA vaccine induces protective immunity against MERS virus in animal study

Medicaid could save billions as patents for several blockbuster antipsychotic medications expire

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

PharmaMar to market and distribute APLIDIN drug candidate in Australia, New Zealand

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

New scientific conference 'Aspirin in the 21st Century' to be held in London

S1 Biopharma supports FDA's approval of flibanserin for women living with HSDD

IQWiG finds no added benefit for safinamide in Parkinson disease

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News